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Abstract: Agitation is one of the most devastating behavioral symptoms in demented patients 
but there is little evidence about effective and safe pharmacotherapy. We aimed to determine 
the effectiveness and safety of mirtazapine in treatment of agitated patients with Alzheimer’s 
disease (AD). The consecutive patients with AD who have signiﬁ  cant agitation were assigned 
to a 12-week open-label, prospective study. Patients received mirtazapine 15–30 mg/day. The 
changes in Cohen-Mansﬁ  eld Agitation Inventory-Short form (CMAI-SF) scores were primary 
outcome measurement. The change in Clinical Global Impression-Severity scale (CGI-S) scores 
and tolerability-safety proﬁ  le were the secondary efﬁ  cacy variables. Thirteen of 16 (81.25%) 
patients completed the study. There was a signiﬁ  cant reduction in CMAI-SF and CGI-S between 
the pre- and post-treatment with mirtzapaine (p  0.001). The mean baseline score was 26.54 
(±5.4) and mean reduction was 10.6 (±7.5) in CMAI-SF. There was no signiﬁ  cant side effect 
and cognitive deterioration. The results of this open-label pilot study suggest that mirtazapine 
may be an effective choice for treatment of agitated patients with AD.
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Introduction
Patients with Alzheimer disease (AD) present various psychological and behavioral 
symptoms. Agitation is commonly seen and has exhaustive effects on both patients 
and caregivers; it causes high morbidity, low quality of life, disturbances in medical 
care, and higher costs. The estimated prevalence of agitation in patients with AD is 
changing between from 67.5% to 82% (Ballard et al 2001; Tractenberg et al 2002). 
The variability of the symptom distribution causes diagnostic difﬁ  culties and makes 
ineffective management interventions more likely. The pharmacological treatments 
need careful evaluation because of ﬂ  uctuating nature of the agitation, unwanted drug 
interactions, and serious adverse events in elderly. Therefore intervention and treatment 
of agitation is essential in patients with dementia.
Mirtazapine is a noradrenergic and speciﬁ  c serotonergic antidepressant (NaSSA) 
that acts as an antagonist at central presynaptic α2 adrenergic inhibitory autoreceptors 
and heteroreceptors. This interaction causes increase in central noradrenergic and 
serotonergic activity. Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors. 
The 5-HT2 blocking effect is related to its anxiolytic effects and its beneﬁ  ts on sleep. 
It was reported that depressed elderly patients on mirtazapine treatment were less 
likely to be taking a sedative/hypnotic drugs (Gardner et al 2004). The enhancement 
effect of seretonergic neurotransmission may be associated with the antiagitation, 
antiimpulsivity effect of the molecule. Antidepressant effects of mirtazapine in geriatric 
patients were studied but there is no study of its effects in treatment of agitation with 
dementia (Schatzberg et al 2002; Roose et al 2003). The present study was conducted Neuropsychiatric Disease and Treatment 2008:4(5) 964
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to investigate the efﬁ  cacy of mirtazapine in agitated patient 
with AD.
Materials and methods
This 12-week open-label, prospective study was conducted 
between January 2006 and July 2007. Informed consents 
were obtained from patients and families. Sixteen community 
dwelling consecutive patients (having a close supervision 
or caring assistance) with AD (DSM-IV criteria) who had 
clinically signiﬁ  cant agitation were enrolled to the study. 
Diagnosis of AD was done by a comprehensive neuropsy-
chiatric evaluation that consists of clinical examination, 
neuropsychological tests, magnetic resonance imaging scans, 
and blood biochemistry.
Agitated patients who had delirium, severe or uncontrolled 
medical illness, and liver or kidney dysfunctions were 
excluded from the study. Other comorbid primary psychiatric 
diagnoses such as schizophrenia and bipolar disorder were 
also exclusion criteria.
The four different types of agitation: physically aggres-
sive behaviors, physically nonaggressive behaviors, verbally 
aggressive behaviors, and verbally nonaggressive behaviors 
were assessed by Cohen-Mansﬁ  eld Agitation Inventory-Short 
form (CMAI-SF) (Cohen-Mansﬁ  eld et al 1986; 1996). It 
includes 14 aggressive behaviors graded on a 5-point scale. 
The caregivers were educated to complete the CMAI-SF at 
baseline and during the study they were checked by another 
physician.
Clinical Global Impression-Severity scale (CGI-S) and 
adverse effects-tolerability proﬁ  le were secondary outcome 
measures. The changes in depressive symptoms and cognition 
were followed up with Geriatric Depression Scale (GDS) and 
Mini-Mental State Examination (MMSE) during the study. 
All these measurements were done by a another physician 
independently from the prescribing physician.
The antipsychotic, antidepressant, and anxiolitic 
medications that were given for agitation treatment and gave 
the impression they were ineffective despite an optimum 
time and dosage were stopped before the study. After a 
wash-out period, the study drug was started. The concomitant 
cholinesterase inhibitors and memantine were continued 
during the study.
Mirtazapine was started with 15 mg/day orally at bed 
time. In the patients who did not respond to 15 mg, the dosage 
were increased to 30 mg at the end of the 2nd week. The 
dosage was ﬂ  exible between 15–30 mg and the maximum 
dosage was 30 mg. Follow up visits were done at 1 week 
(over the telephone), and at 2, 4, 8, and 12 weeks. The study 
group was checked for interim adverse events at every visit. 
Safety assessments were done with collecting all adverse 
events, laboratory tests. Liver enzymes, kidney function, 
and other biochemical tests were checked before the study 
and at the end of the study.
Data analysis
Descriptive and comparison statistics from baseline to 
post-treatment were used as a primary method to conclude 
the results. Changes in primary and secondary efﬁ  cacy 
measurements were collected to asses the effectiveness. 
Paired t tests were used to analysis of effectiveness between 
the baseline and 2, 8, and 12 weeks. P value lower than 
0.05 was considered signiﬁ  cant.
Results
Demographic and clinical features
Sixteen patients were enrolled and 13 patients completed 
the study (81.25%). The demographic and clinical data 
are summarized in Table 1. Twelve female (75%) and 
4 male (25%) patients, aged between 66–86 (mean 73.6, 
SD ± 6.36), with moderate (n = 10) or severe (n = 6) AD 
had significant agitation. The mean duration of agita-
tion was 7.2 weeks at baseline. Half of the patients had 
psychotic symptoms; 4 patients had delusions, 3 patients 
had both delusions and hallucinations, and 1 had only 
hallucinations. In 6 of 8 patients, agitation was started after 
the psychotic symptoms. Verbal agitation was signiﬁ  cant 
(n = 12). Twelve of the patients were on cholinesterase 
inhibitors (7 donepezile, 5 rivastigmine), 4 patients were 
on cholinesterase inhibitors and the N-methyl D-aspartate-
receptor antagonist, memantine.
Six patients had been taking 15 mg/day mirtazapine, the 
dosage was increased to the 30 mg/day in 7 patients at the 
end of second week. Three patients discontinued in the ﬁ  rst 
week of the treatment.
Improvements on the outcome 
measurements
The CMAI-SF score was 26.54 (range: 17 to 36, SD ± 5.4), 
CGI-S was 4.54 (range: 3 to 6, SD ± 0.9) at baseline (Table 1). 
Mean GDS score was 10.5 (range: 6 to 16, SD ± 3.3) and 
MMSE was 16.8 (range: 9 to 23, SD ± 3.9) at baseline. 
Among the completers, 11 patients were much or very much 
improved, 2 patients were minimally improved.
Table 2 shows the changes in primary and secondary 
outcome measurements. Total CMAI-SF score signiﬁ  cantly Neuropsychiatric Disease and Treatment 2008:4(5) 965
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decreased starting from the 2nd week of treatment (p  0.002). 
Total CMAI-SF improved by 20%–45% at second week and 
by 41.35% at the end of study.
There was a statistically significant improvement 
between baseline and 12th week in both CGI-S and 
CMAI-SF scores (p  0.001). The mean change in CMAI-SF 
was −11.0 (SD  ± 7.5) and −2.0 (SD  ±  0.9) in CGI-S, p value 
was 0.001 in both. The mean change was 0.85 at GDS, it 
was not signiﬁ  cant (p = 0.055). There was no correlation 
between the GDS and CMAI-SF (r = 0.03).
Safety, tolerability, and adverse events
Three patients could not tolerate the study drug and dropped 
out because of sedation (n = 2), fatigue (n = 1), or dizziness 
(n = 1). These complaints were seen with 15 mg in 3 patients 
at the ﬁ  rst week of the treatment. Sedation disappeared when 
the dosage was increased from 15 mg to 30 mg in a patient 
and they could continue the study.
We did not observe signiﬁ  cant weight gain. Two patients 
had mild orthostatic hypotension but the relation between the 
hypotension and study drug was not clear, since hypoten-
sion continued after the end of study. One patient reported 
headache with 30 mg, which disappeared with a decrease of 
dosage to 15 mg. At the end of study, there was no change 
in blood biochemistry in any of the patients. There was also 
no change in MMSE scores.
Discussion
This open-label pilot study indicated that mirtazapine could 
be an option for treatment of agitation in patients with AD. To 
our knowledge this is ﬁ  rst study in the literature to research 
the efﬁ  cacy of mirtazapine in the treatment of agitation in 
patients with AD.
Thirteen of 16 patients completed the study and 3 dropped 
out within the ﬁ  rst week of the study. The drop-out rate 
(18.8 %) can be considered as minimal in this study as in 
other dementia studies with atypical antipsychotics drop-
out rate was reported 1/3 and 77%–85% (Schneider et al 
2006a, 2006b).
The side-effect proﬁ  le of mirtazapine was mild in this 
study. Sedation, headache, and mild hypotension were seen 
and these were managed with close monitoring. A more 
regular appetite was reported by caregivers but no differ-
ence in weight was found. Agitation may precipitate the loss 
of appetite. The increased appetite and weight gain with 
mirtazapine in elderly can be less than in young patients 
as a report in elderly depressed patients showed (Nelson 
et al 2006).
The recent pharmacologic studies to manage the 
agitation in dementia showed unsatisfactory results. 
Atypical antipsychotics have serious side effects such 
as cerebrovascular events and extrapyramidal symptoms 
(SchneIder et al 2005; Ballard et al 2006). The remained 
options also do not have promising effectiveness. 
Benzodiazepines are known to increase the cognitive 
impairments and falls (Golombok et al 1988; Ray et al 
1989). Donepezil also did not show any difference than 
placebo for the treatment of agitation (Howard et al 2007). 
Despite the recent positive result of valproat in some 
selective physical aggression and irritability subitems, a 
placebo-controlled study did not show its effectiveness in 
management of agitation (Herrmann et al 2007).
Table 1 Demographic and clinical features of study group
The number of patients participated (n)  16
The number of completers (n)  13
Mean age (SD)  73.6 (±6.36)
Female gender n (%)  12 (75%)
Severity of AD 
– Moderate (n)  10
– Severe (n)  6
Mean duration of agitation (weeks)  7.2
Mean mirtazapine dosage (mg/day)  23.08
– Patients with psychotic symptoms (n)  8
– Delusions  4
– Hallucinations  3
– Delusions and hallucinations  1
Abbreviations: AD,  Alzheimer’s disease;  SD, standard deviation.
Table 2 Scores and changes in efﬁ  cacy variables
  Baseline 2nd week 8th week 12th week p*
CMAI-SF (SD) 26.50 (5.4) 21.08 (4.4) 15.62 (3.9) 15.54 (3.8) 0.001
CGI-S (SD) 4.56 (0.9) 3.46 (0.9) 2.62 (0.65) 2.54 (0.6) 0.001
GDS (SD) 10.5 (3.3) 10.46 (2.7) 9.8 (2.5) 9.65 (2.8) ns
MMSE (SD) 16.8 (3.9) 18.15 (2.5) 18.6 (2.4) 18.53 (2.5) ns
Note: p* baseline and 12th week.
Abbreviations: CGI-S, Clinical Global Impression-Severity scale; CMAI-SF, Cohen-Mansﬁ  eld Agitation Inventory-Short form; GDS, Geriatric Dementia Scale; MMSE, Mini 
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There are some reports showed serotoninergic 
psychotropic agents like trazadone, citalopram, or paroksetin 
could be useful in treatment of agitation (Pollock et al 
1997; Ramadan 2000). In our opinion, mirtazapine could 
make a step forward for previously studied agents. While 
selective serotonin reuptake inhibitors activates serotonin 
receptors of the 2 and 3 subclasses, mirtazapine blocks them, 
and this feature may result in fewer complaints related to 
sleep and arousal and this may work as an advantage. In 
addition, endocrine effects of mirtazapine, particularly on the 
hypothalamic-pituitary-adrenal system and melatonin, may 
be related to its sleep-promoting action and helps improve 
the agitation (Schmid et al 2006).
It was thought that agitation was related to the sleep 
disorders (Cohen-Mansﬁ  eld et al 2000). Our observations 
were also similar; agitation was seen during the night in 
most of patients. The sedative effects of mirtazapine may 
help to decrease the agitation during the night. If sleep 
disturbances are solved, agitation can be decreased also 
during the day. The results of this study are in line with this 
opinion. Mirtazapine could be beneﬁ  cial especially in those 
who need a sedating agent or in patients whose agitation is 
signiﬁ  cant at night time. In this study the depression is not 
signiﬁ  cant among the patients and was not the main target 
of the treatment. Psychotic symptoms, depression, and 
agitation can make an amalgam that induces each other and 
create complexity especially in the later stages of dementia. 
To start the treatment for agitation with this complex would 
be beneﬁ  cial as a urgent and safe intervention. A double 
blinded study found that antidepressant effect of mirtazapine 
started earlier than paroxetine in elderly depressed patients 
(Schatzberg et al 2002). This study supports our suggestion 
that mirtazapine with its short action time may improve 
current therapeutic practices.
The 12-week duration was considered an optimal period 
to decide the efﬁ  cacy of the study drug even although there 
may be a ﬂ  uctuating nature of agitation because of the 
unwanted effects of psychotropic drugs in elderly.
Similarly to the other studies which included elderly AD 
patients, this study had some methodological difﬁ  culties; 
small case numbers, being an open study, a lack of placebo 
control, and the short duration.
In conclusion, even though it was an open-label study, 
this prospective, pilot study indicated that patients with AD 
who have signiﬁ  cant agitation can be treated with mirtazapine 
without signiﬁ  cant adverse events or cognitive deterioration. 
Therefore controlled studies with a larger number of cases 
are needed.
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